Device-Free Auricular Acupressure for Rosacea: A Randomized Clinical Trial.

1. JAMA Dermatol. 2026 Oct 14:e263999. doi: 10.1001/jamadermatol.2026.3999. Online ahead of print. Device-Free Auricular Acupressure for Rosacea: A Randomized Clinical Trial. Xu B(1), Chu J(2), Wang Y(3), Wang Y(1), Li L(4), Yang Y(1), Yu B(5), Xiao T(1), Yang P(1), Wu N(6), Sun H(7), Xiao S(1), Xia Y(1), An P(4), Zhang T(2), Wu J(1). Author information: (1)Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. (2)Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China. (3)Department of Geriatric Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. (4)Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. (5)Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shi'yan, China. (6)Department of Nursing, Xi'an Jiaotong University Health Science Center, Xi'an, China. (7)Department of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. IMPORTANCE: Transcutaneous auricular vagus nerve stimulation is effective for rosacea. However, its neuroimmunomodulatory effects lack sham-controlled serum biochemical evidence, and specialized device reliance limits its clinical popularization. OBJECTIVE: To evaluate the clinical efficacy of device-free auricular acupressure for rosacea and verify its neuroimmunomodulatory effects using serum biomarkers and immediate vascular imaging in a sham-controlled trial. DESIGN, SETTING, AND PARTICIPANTS: This single-center, randomized, sham-controlled, assessor-masked trial was conducted in the Dermatology Outpatient Department of the Second Affiliated Hospital of Xi'an Jiaotong University from October 2025 to May 2026 and included 204 patients with rosacea who were receiving standard first-line treatment. Participants were assigned in a 1:1 ratio using block randomization. Data analysis was initiated in May 2026. INTERVENTIONS: The active acupressure group received a Vaccaria segetalis seed on the bilateral cavum conchae (innervated by the auricular vagus branch), while the sham group received a seed on the auricular tubercle superior margin (pure somatosensory innervation). Participants performed acupressure 3 times daily for 30 seconds, with extra pressing allowed during acute flare-ups. The intervention lasted 8 weeks. Serum levels of cathelicidin antimicrobial peptide (LL-37), calcitonin gene-related peptide (CGRP), tumor necrosis factor α (TNF-α), and interleukin (IL) 6 were measured at baseline and week 8. Multispectral imaging was performed at baseline and week 4 to assess immediate vascular responses. MAIN OUTCOMES AND MEASURES: The primary outcome was treatment success, defined as an Investigator Global Assessment (IGA) score of 0 or 1 at week 8. The number needed to treat was calculated from absolute risk difference. RESULTS: The 204 participants were equally divided into 2 groups (102 each; active acupressure: mean [SD] age, 32.51 [10.60] years, 86 female individuals [84.3%]; sham acupressure: mean [SD] age, 30.82 [9.32] years, 86 female individuals [84.3%]). At week 8, the active acupressure group had a higher IGA success rate (58 [56.9%] vs 36 [35.3%]; relative risk, 1.61; 95% CI, 1.18-2.20; P = .003; number needed to treat, 5). Serum LL-37, CGRP, TNF-α, and IL-6 levels decreased more significantly in the active acupressure group. The immediate vascular improvement rate was 59.3% vs 7.4% (P < .001). At week 20, the active acupressure group maintained significantly lower IGA and Clinical Erythema Assessment scores. No serious adverse events occurred. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that device-free, on-demand intervention yielded substantial additional clinical benefits when combined with standard first-line therapy and established early sham-controlled, serum-based evidence for its neuroimmunomodulatory mechanism, potentially offering a strategy for self-management of rosacea. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2500110787. DOI: 10.1001/jamadermatol.2026.3999 PMCID: PMC13670125 PMID: 42873508 Conflict of interest statement: Conflict of Interest Disclosures: None reported.